Sirolimus (Rapamune) in renal transplantation

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Long-term graft survival in transplantation is increasingly prioritized over short-term outcomes.
• Calcineurin antagonists, while effective, cause nephrotoxicity, a significant factor in late graft loss.
• Sirolimus has emerged as a valuable agent in managing immunosuppression post-transplant.

Purpose of the Study:

• To evaluate sirolimus as a replacement for calcineurin inhibitors in long-term transplant maintenance.
• To assess the impact of combining sirolimus with cyclosporine on patient and graft outcomes.
• To investigate the synergistic effects of sirolimus and cyclosporine on both therapeutic and adverse effects.

Main Methods:

• Review of recent studies on sirolimus use in transplantation.
• Analysis of patient and graft survival rates at 24 months.
• Comparison of renal function, blood pressure, and lipid profiles in patients on different immunosuppressive regimens.

Main Results:

• Sirolimus allows successful weaning from cyclosporine, with excellent patient and graft survival.
• Improvement in renal function and resolution of side effects like hirsutism and gum hyperplasia observed with sirolimus.
• Combination therapy with cyclosporine and sirolimus resulted in increased blood pressure, nephrotoxicity, and hyperuricemia.

Conclusions:

• Sirolimus is a viable alternative to cyclosporine or tacrolimus for long-term maintenance immunosuppression.
• Combining sirolimus with cyclosporine potentiates adverse effects, including nephrotoxicity and hyperlipidemia.
• Careful consideration of drug interactions is crucial when using sirolimus in combination regimens.